Table 1.
The effects of crocin on various cell lines (cytotoxic) and animal model (anti-tumor)
| References | Cell type | Concentration or dose/duration/ animal | Study design | Target system |
|---|---|---|---|---|
| ( 33 ) | HCT-116, HT-29 & SW-480 | 0.03,0.1,0.3 & 1.0 Mm | Cell line study | Colon |
| ( 34 ) | HCT116 & HCT116 p53−/− | 10 Mml 24 & 48 hr/rat | Cell line study | Colon |
| ( 48 ) | - | 50,100 & 200 ppm/15 weeks in diet/mice | Colonic adenocarcinoma induction by DSS | Colon |
| ( 49 ) | MCF-7 | 10,25,50 µg/ml/24 hr/human | Cell line study | Breast |
| ( 50 ) | MDA-MB-468 | 0-5 mg/ml/0-72 hr/human | Cell line study | Breast |
| ( 51 ) | MCF-7 | 2.5 mg/ml/48 hr/human | Cell line study | Breast |
| ( 52 ) | A549 & SPC-A1 | 1,2,4,8,16 mg/ml/human | Cell line study | Lung |
| ( 53 ) | PC3 & 22rv1 | 200 mg/kg /PO/ 5 day/week/human | Cancer cells | Prostate |
| ( 54 ) | LnCaP, 22rv1, CRW PC3 & 145 DU | 0.1-4 Mm/48 hr/human | Cell line study | Prostate |
| ( 55 ) | HepG2 | 3 mg/ml/48 hr/human | Cell line study | Liver |
| (56) | Hella | Crocin: 1, 2 & 4 mM crocin liposomal forms: 0.5 & 1 mM/24, 48 hr & 72 hr/ human |
Cell line study | Cervix |
| (57) | Tca8113 | 0.01, 0.2 , 0.4 & 0.8 mM 24, 48, 72, & 96 hr/human | Cell line study | Tongue |